XBIOTECH INC.
Income Statement
| Line Item | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|
| Revenue | $0 | $4.0M | $18.4M | $44.0M | $0 | $0 |
| Cost of Revenue | $0 | $651.0K | $5.8M | $34.5M | $0 | $0 |
| Gross Profit | $0 | $3.4M | $12.6M | $9.4M | $0 | $0 |
| Gross Margin | — | 83.8% | 68.4% | 21.5% | — | — |
| Operating Expenses | ||||||
| Research & Development | $32.8M | $31.5M | $28.3M | $9.5M | $24.1M | $15.7M |
| SG&A Expense | $4.7M | $6.3M | $9.4M | $18.2M | $7.1M | $5.3M |
| Operating Income | $-37.5M | $-34.5M | $-25.1M | $-18.3M | $-31.2M | $-21.0M |
| Operating Margin | — | -860.1% | -136.4% | -41.5% | — | — |
| Interest Expense | — | — | — | — | — | — |
| Pretax Income | $-24.3M | $-33.6M | $-25.5M | $-12.8M | $718.5M | $-21.1M |
| Income Tax Expense | $244.0K | $-688.0K | $-8.0M | $-1.6M | $49.8M | $0 |
| Net Income | $-24.6M | $-32.9M | $-17.4M | $-11.2M | $668.6M | $-21.1M |
| Net Margin | — | -820.4% | -94.7% | -25.5% | — | — |
| EPS (Basic) | $-0.81 | $-1.08 | $-0.58 | $-0.36 | $17.17 | $-0.59 |
| EPS (Diluted) | $-0.81 | $-1.08 | $-0.58 | $-0.36 | $14.44 | $-0.59 |
| Shares Outstanding (Basic) | 30.4M | 30.4M | 30.0M | 30.8M | 38.9M | 35.8M |
| Shares Outstanding (Diluted) | 30.4M | 30.4M | 30.0M | 30.8M | 46.3M | 35.8M |
| Dividends Per Share | — | — | — | — | — | — |